Alcon Receives FDA Approval for AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL with Activefocus

Source: Alcon

Alcon has received approval from the FDA for its AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL with Activefocus, which is designed to address astigmatism and presbyopia at the same time. The unique optical design of the Activefocus toric lens delivers both crisp, clear distance vision and a range of vision for patients who desire less dependence on glasses. The Activefocus toric IOL is the only multifocal toric IOL in which the central portion is 100 percent dedicated to distance vision, according to Alcon.

"Presbyopic cataract patients with astigmatism have had limited options in the past," Sergio Duplan, Region President, North America for Alcon, said in a company news release. "Alcon's Activefocus toric IOL is a breakthrough for these patients, correcting astigmatism and allowing them to achieve uncompromised distance vision with an increased range of vision at the same time."

The Activefocus toric IOL is also engineered for stability. Toric IOLs perform optimally if they stay on axis to correct the astigmatism. In a retrospective study of IOL orientation data, the AcrySof IQ toric IOL platform was 2.5 times less likely to rotate than the leading competitor lens. Additionally, the AcrySof IQ toric platform is the market leader with cataract surgeons implanting more than 1.7 million AcrySof IQ toric IOLs to date, according to the news release.

"The Activefocus toric IOL is the marriage of the design features of my two go-to IOLs for patients wanting outstanding distance vision and less dependence on glasses after cataract surgery," Bret L. Fisher, MD, Medical Director, Eye Center of North Florida, said in the news release. "By combining the unique optical properties of the Activefocus design with the unparalleled rotational stability of the AcrySof IQ toric platform, I can now offer a range of vision to more patients."

Alcon plans to commercialize the Activefocus toric IOL in the United States beginning in mid-2017.

Related Content